Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comfrey

This article was originally published in The Tan Sheet

Executive Summary

FTC action July 13 against comfrey marketer Western Botanicals (Fair Oaks, Calif.) is second one in two weeks. Decision is part of commission's "Operation Cure.All" crackdown on unsupported supplement claims. Stipulated permanent injunction bars defendant from future sale of internal comfrey products, external products without warnings; Western also is required to notify distributors, purchasers by mail. FDA issued a comfrey advisory July 6 following FTC action against comfrey supplement marketer Christopher Enterprises (1"The Tan Sheet" July 9, p. 10). Several trade groups have voiced support for comfrey actions and pointed to voluntary label programs already in place

You may also be interested in...



CAM Labs' Use Of Unestablished Tests Largely Unregulated, HHS IG Reports

Complementary and alternative medicine laboratories practicing live blood cell analysis (LBA) and other unestablished diagnostic tests could face increased federal enforcement following a recent report by the HHS Office of the Inspector General.

CAM Labs' Use Of Unestablished Tests Largely Unregulated, HHS IG Reports

Complementary and alternative medicine laboratories practicing live blood cell analysis (LBA) and other unestablished diagnostic tests could face increased federal enforcement following a recent report by the HHS Office of the Inspector General.

CAM Labs' Use Of Unestablished Tests Largely Unregulated, HHS IG Reports

Complementary and alternative medicine laboratories practicing live blood cell analysis (LBA) and other unestablished diagnostic tests could face increased federal enforcement following a recent report by the HHS Office of the Inspector General.

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel